These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38807448)

  • 1. The impact of emergency guidance to the COVID-19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine.
    Ivasiy R; Madden LM; Meteliuk A; Machavariani E; Ahmad B; Zelenev A; Desai MM; Bromberg DJ; Polonsky M; Galvez de Leon SJ; Farnum SO; Islam Z; Altice FL
    Addiction; 2024 Sep; 119(9):1585-1596. PubMed ID: 38807448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
    Kutsa O; Marcus R; Bojko MJ; Zelenev A; Mazhnaya A; Dvoriak S; Filippovych S; Altice FL
    J Int AIDS Soc; 2016; 19(4 Suppl 3):20897. PubMed ID: 27435717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
    Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL
    J Subst Abuse Treat; 2021 Feb; 121():108164. PubMed ID: 33191004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.
    Tan J; Altice FL; Madden LM; Zelenev A
    Lancet HIV; 2020 Feb; 7(2):e121-e128. PubMed ID: 31879250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
    Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
    J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.
    Bojko MJ; Mazhnaya A; Marcus R; Makarenko I; Islam Z; Filippovych S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2016 Jul; 66():37-47. PubMed ID: 27211995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
    Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
    Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine.
    Morozova O; Dvoryak S; Altice FL
    Int J Drug Policy; 2013 Nov; 24(6):e91-8. PubMed ID: 24360402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study.
    Lambdin BH; Masao F; Chang O; Kaduri P; Mbwambo J; Magimba A; Sabuni N; Bruce RD
    Clin Infect Dis; 2014 Sep; 59(5):735-42. PubMed ID: 24855149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda.
    Mudiope P; Mutamba BB; Komuhangi L; Nangendo J; Alamo S; Mathers B; Makumbi F; Wanyenze R
    Addict Sci Clin Pract; 2024 May; 19(1):39. PubMed ID: 38750568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.
    Dumchev K; Dvoryak S; Chernova O; Morozova O; Altice FL
    Int J Drug Policy; 2017 Oct; 48():44-53. PubMed ID: 28800420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.
    Morozova O; Crawford FW; Cohen T; Paltiel AD; Altice FL
    Addiction; 2020 Mar; 115(3):437-450. PubMed ID: 31478285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.